nilotinib FDA Link

antineoplastic agent

Also Known As:

4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide; AMN 107; AMN-107; AMN107; Tasigna; benzamide, 4- methyl- N- (3- (4- methyl- 1H- imidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- (3- pyridinyl)- 2- pyrimidinyl)amino)- , hydrochloride (1:1); benzamide, 4- methyl- N- (3- (4- methyl- 1H- imidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- (3- pyridinyl)- 2- pyrimidinyl)amino)- , hydrochloride, hydrate; benzamide, 4- methyl- N- (3- (4- methyl- 1H- imidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- (3- pyridinyl)- 2- pyrimidinyl)amino)- , hydrochloride, hydrate (1:1:2); benzamide, 4- methyl- N- (3- (4- methyl- 1H- imidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- (3- pyridinyl)- 2- pyrimidinyl)amino)- , hydrochloride, hydrate (1:2:2); benzamide, 4- methyl- N- (3- (4- methyl- 1H- imidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- (3- pyridinyl)- 2- pyrimidinyl)amino)- , hydrochloride, hydrate (2:2:3); nilotinib dihydrochloride dihydrate; nilotinib hydrochloride; nilotinib hydrochloride anhydrous; nilotinib hydrochloride dihydrate; nilotinib hydrochloride hydrate; nilotinib hydrochloride monohydrate; nilotinib hydrochloride sesquihydrate

Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 521
    - nilotinib: 1166

C Straub Selected Research

C Straub Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure